Page last updated: 2024-12-09

1-(3-chlorophenyl)sulfonylpyrrolidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-(3-chlorophenyl)sulfonylpyrrolidine is a chemical compound with the molecular formula C₁₀H₁₂ClNO₂S.

It is a **sulfonamide derivative**, specifically a **pyrrolidine sulfonamide**, with a 3-chlorophenyl substituent attached to the sulfonyl group.

**Importance in Research:**

While I couldn't find specific research on 1-(3-chlorophenyl)sulfonylpyrrolidine itself, **sulfonamides** in general are important in research due to their diverse applications:

* **Pharmaceutical Chemistry:** Sulfonamides are widely used as **antibacterial agents** (e.g., sulfa drugs). They inhibit the synthesis of folic acid, an essential nutrient for bacterial growth.
* **Organic Synthesis:** Sulfonamides are versatile intermediates in organic synthesis. They can be used to prepare various other compounds through reactions like **sulfonylation**, **amidation**, and **cyclization**.
* **Materials Science:** Sulfonamides are also used in the development of **polymers**, **surfactants**, and **dyes**.

**Potential Applications of 1-(3-chlorophenyl)sulfonylpyrrolidine:**

Considering the compound's structure, it could potentially be investigated for:

* **Pharmacological activity:** The pyrrolidine ring is often found in **medicinal compounds**, and the sulfonamide group could contribute to potential **biological activity**.
* **Synthetic chemistry:** As a sulfonamide, it could serve as a building block for preparing novel compounds with diverse functionalities.
* **Material science:** The presence of the sulfonyl group and the aromatic ring could make it useful in the synthesis of polymers or other materials.

**It's important to note:**

* Without specific research on 1-(3-chlorophenyl)sulfonylpyrrolidine, its actual properties and applications remain unknown.
* Research on this specific compound would need to be conducted to determine its potential uses.

I hope this explanation is helpful!

Cross-References

ID SourceID
PubMed CID890981
CHEMBL ID1334769
CHEBI ID109831
SCHEMBL ID15010078

Synonyms (20)

Synonym
SDCCGMLS-0046385.P002
MLS000063405 ,
smr000072725
1-[(3-chlorophenyl)sulfonyl]pyrrolidine
CHEBI:109831
AKOS000812279
1-(3-chlorophenyl)sulfonylpyrrolidine
HMS2457E03
CHEMBL1334769
SCHEMBL15010078
bdbm31033
cid_890981
Q27189133
SR-01000262918-1
sr-01000262918
670271-99-5
1-(3-chlorobenzenesulfonyl)pyrrolidine
CS-0352025
1-((3-chlorophenyl)sulfonyl)pyrrolidine
Z45509034
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency0.05620.011212.4002100.0000AID1030
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1AHomo sapiens (human)EC50 (µMol)50.00000.07001.46505.1000AID718
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)EC50 (µMol)50.00000.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)EC50 (µMol)50.00000.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)EC50 (µMol)50.00000.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)EC50 (µMol)50.00000.01901.73677.0000AID718
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)EC50 (µMol)50.00000.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)EC50 (µMol)50.00000.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)EC50 (µMol)50.00000.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)EC50 (µMol)50.00000.00011.46937.0000AID718
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)EC50 (µMol)50.00000.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)EC50 (µMol)50.00000.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)EC50 (µMol)50.00000.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)EC50 (µMol)50.00000.01902.149910.0000AID718
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)EC50 (µMol)50.00000.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)EC50 (µMol)50.00000.01901.73677.0000AID718
GABA theta subunitRattus norvegicus (Norway rat)EC50 (µMol)50.00000.01901.70547.0000AID718
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)EC50 (µMol)50.00000.01901.70547.0000AID718
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1333780Anticonvulsant activity in Carworth Farm1 mouse assessed as protection against maximal electroshock-induced seizures at 100 mg/kg, ip administered 30 mins prior to 60-Hz current induction2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Simple N,N-dimethyl phenylsulfonamides show potent anticonvulsant effect in two standard epilepsy models.
AID1333778Neurotoxicity in Carworth Farm1 mouse assessed as muscle relaxation up to 100 mg/kg, ip2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Simple N,N-dimethyl phenylsulfonamides show potent anticonvulsant effect in two standard epilepsy models.
AID1333776Neurotoxicity in Carworth Farm1 mouse assessed as somnolence up to 100 mg/kg, ip2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Simple N,N-dimethyl phenylsulfonamides show potent anticonvulsant effect in two standard epilepsy models.
AID1333777Neurotoxicity in Carworth Farm1 mouse assessed as sedation up to 100 mg/kg, ip2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Simple N,N-dimethyl phenylsulfonamides show potent anticonvulsant effect in two standard epilepsy models.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.35 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]